Rentschler Biopharma Kicks off Expansion at U.S. Facility in the Boston Biotech Hub

- New 500 L bioreactor in operation mid-2020 at U.S. site

- Company's clinical and commercial manufacturing capabilities to be showcased during BIO-Europe^(R), November 11-13 in Hamburg, Germany

Laupheim, Germany and Milford, MA, USA, November 6, 2019 - Rentschler Biopharma SE, a world-class contract development and manufacturing organization (CDMO) for biopharmaceuticals, is taking the first step in the expansion project to grow its U.S. footprint and establish a Center of Excellence in North America, putting into operation a single-use bioreactor for the 93,000 square foot facility in Milford, MA, in the Greater Boston area.

The XDR-500 bioreactor, with a working volume of 100-500 L and down stream process capabilities of 2-8 g/L, is part of the state-of-the-art GMP facility suite concept. The system is planned to be client-ready in mid-2020 and is currently being prepared for technology transfer. With its innovative and highly flexible business model, the Milford site is already taking on new projects, including complex and difficult-to-manufacture proteins, e.g. multispecific antibodies.

Further expansion planning includes another building for large-scale manufacturing, which will also be single-use bioreactor manufacturing as well as lab capacity for new modalities. Both, in Europe and the U.S., Rentschler Biopharma will be able to leverage its client-centric approach and expertise in advanced technologies to facilitate the robust and scalable production of complex biomolecules.

Dr. Jesús Zurdo, Senior Vice President Innovation and Venture Partnerships, will bring to BIO-Europe^(R) Rentschler Biopharma's knowledge and dedication to science as a foundation to convert medical research into outstanding biopharmaceuticals. In the workshop "", Dr. Zurdo, together with other experienced executives, will discuss the implementation of the best business models and technological innovations to follow the most efficient path in new drug development, including innovative manufacturing solutions.

Rentschler Biopharma events at Bio-Europe^(R):

- Dr. Jesús Zurdo, Senior Vice President Innovation and Venture Partnerships, will address speed to clinic, fit for purpose development and early risk assessment as part of the workshop "": November 11, at 9:00 AM, Level 1, Hall B1, Room 6

- Exhibit Hall Hospitality Reception, November 12, 5:45 PM, Hall B2, Booth 53

- Federico Pollano, Senior Vice President Business Development, and his team are looking forward to meeting with you at the Rentschler Biopharma booth (#53, Hall B2)

About Rentschler Biopharma SE
Rentschler Biopharma, is a leading contract development and manufacturing organization (CDMO), focused exclusively on client projects. From its headquarters in Laupheim, Germany, and its site in Milford, MA, USA, Rentschler Biopharma offers process development and manufacturing of biopharmaceuticals as well as related consulting activities, including project management and regulatory support. Rentschler Biopharma's high quality is proven by its long-standing experience and excellence as a solution partner for its clients. A high-level quality management system, a well-established operational excellence philosophy and advanced technologies ensure product quality and productivity at each development and manufacturing step. In order to offer optimal solutions across the entire value chain, the Company has entered into a strategic alliance with Leukocare AG for formulation development and with Rentschler Fill Solutions GmbH for fill & finish services. Rentschler Biopharma is a family-owned company with more than 850 employees. For further information, please visit .

About BIO-Europe^(R)
BIO-Europe^(R) is the preeminent partnering conference of the European life science industry, bringing together international decision makers from the biotechnology, pharmaceutical and financial sectors, offering networking opportunities and private one-to-one meetings. The BIO-Europe^(R) 2019 partnering event is expected to bring together 4,400 executives from more than 2,300 life sciences companies from over 60 countries. To learn more about the conference, please visit .